Find and Pitch Jounalists, Get Your Story Covered

Tags: enterprise accelerators open source ai hardware

	Profile	Recent Articles on Subject
1	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease - 23 days ago Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - 2 months ago FDA Panel Endorses Donanemab to Treat Early-Stage Alzheimer Disease - 8 months ago FDA Grants Orphan Drug Designation for CAN-2409 to Treat Pancreatic Cancer - 10 months ago
2	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results - about 1 month ago STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug - over 1 year ago
3	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	Ozempic for Alzheimer's? What Drives Brain Age; Primary Care Alzheimer's Guideline - about 1 month ago Alzheimer's Data Withdrawn - 3 months ago Why Alzheimer's Drug Approval Delay? $3 Billion in DMD Gene Therapy; ADHD Prevalence - 10 months ago Opening Blood-Brain Barrier to Deliver Alzheimer's Drug Shows Promise - about 1 year ago Alzheimer's Vaccines Are Back; Streamlining Prior Authorization; Rare APOE Variant - about 1 year ago Subcutaneous Alzheimer's Drug May Be on the Horizon - over 1 year ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news - 2 months ago STAT+: It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials - over 1 year ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	A win for Apellis, a setback for Astellas - 2 months ago The biotech news you missed this week - 7 months ago
6	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about drug shortages, what drugmakers didn’t tell Alzheimer’s trial patients and more - 3 months ago STAT+: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more - 11 months ago STAT+: Pharmalittle: We’re reading about Lilly Alzheimer’s drug adcomm, Amylyx ALS drug flop, and more - 11 months ago STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more - 12 months ago STAT+: In response to criticism, FDA publishes new database of wayward clinical trial sponsors - about 1 year ago STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs - about 1 year ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - over 1 year ago
7	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	Amy Abernethy, former No. 2 at FDA, outlines new company’s plans to streamline clinical research - 4 months ago
8	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped? - 4 months ago 3 recent FDA adcomm rejections — and why they matter - over 1 year ago
9	Nicole Lou MedPage Today Medical reporter @medpagetoday. Bird advocate. undisclosed remote location medical reporting	Ocaliva's Takedown by FDA Panel - 5 months ago
10	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Grants Orphan Drug Designation to AISA-021 for Systemic Sclerosis - 5 months ago Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development - 5 months ago FDA Accepts Supplemental New Drug Application for Adagrasib for Colorectal Cancer - 11 months ago Biogen Reprioritizes Alzheimer Disease Franchise, Discontinuing Aducanumab and Advancing Lecanemab - 12 months ago FDA Accepts Supplemental Biologics License Application for Hadlima for Interchangeability With Humira - about 1 year ago Expert: Improving Efficiency of Biosimilar Operations, Advancing Interchangeable Biosimilar Development Among Top Priorities for FDA - over 1 year ago

Journalists covering FDA accelerated approval ,Office of Inspector General ,aducanumab approval,clinical trial data,alzheimer disease